Carbohydrate absorption inhibitors α glucosidose inhibitors Acarbose Dose Adverse events Relatively complex network controlling PPG Determinants of PPG PPG Preprandial glycaemic level Meal size and meal content ID: 762791
Download Presentation The PPT/PDF document "Carbohydrate absorption inhibitors α -..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Carbohydrate absorption inhibitors α-glucosidose inhibitors Acarbose : Dose Adverse events
Relatively complex network controlling PPG:Determinants of PPG PPG Pre-prandial glycaemic level Meal size and meal content Insulin secretion and insulin sensitivity Glucagon and other counter-regulatory hormones Gastric emptying and incretin hormones FPG, fasting plasma glucose; PPG, postprandial plasma glucose 1. Ceriello . Int J Clin Pract 2010;64:1705–11; 2. Alsahli & Gerich. Ref Mod Biomed Res 2014;doi:10.1016/B978-0-12-801238-3.03827-7
Cephalic phase of insulin secretion1Evoked by the sight, smell and taste of food (before gut absorption) Postprandial biphasic insulin secretion 2:First phase/early phase, transitory:Critical role in PPG homeostasis (targeting the liver) Can prevent chronic postprandial hyperglycaemia (glucotoxicity) and chronic hyperinsulinaemia (beta-cell exhaustion)Second phase, more gradually:Related to the degree and duration of the stimulus β-cell insulin content3: 2–3% released during first phase20% released during second phase Prandial insulin secretion First- and second-phase insulin secretion in the β -cell4 240 Insulin secretion Time (min) 0 5 Second-phase insulin secretion Glucose stimulation First-phase insulin secretion PPG, postprandial plasma glucose Bruce et al . Metabolism 1987;36:721–5; 1. Caumo & Luzi . Am J Physiol Endocrinol Metab 2004;287:E371–85; 2. DelPrato. Diabetologia 2003;46(Suppl. 1):2–8; 3. Cheng et al. Curr Molec Med 2013;13:126–39
Acarbose300 mg Acarbose = 1500 mg Metformin
AcarboseInitially 25 mg po with first bite of meals. Can increase 50-100 mg q8h at 4-8 w, base on:PPG – HbA1C- tolerance.
Prandial insulin secretion 240 Insulin secretion Time (min) 0 5 Second-phase insulin secretion Glucose stimulation First-phase insulin secretion
Maximum Dose:< 60 kg 50 mg q8h> 60 kg 100 mg q8h
Efficacy and safety of combination therapy with an alpha-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis AGI increases GLP-1 secretion. Because DPP4 inhibitor protects GLP-1 and GIP from enzymatic degradation, combination of DPP4 inhibitor and AGI may synergistically increase active GLP-1 levels.
In conclusion, addition of a DPP4 inhibitor to patients with inadequately controlled T2DM with AGI therapy achieved a clinically significant improvement in glycemic control without increasing the risk of weight gain and hypoglycemia. Therefore, this combination should be a viable option in the pharmacological therapy for T2DM .